Bristol-myers Squibb Compnay

Viiv Healthcare UK (no.5) Limited

Bristol-myers Company

Bristol Meyers Squibb Company

Other

Virginia Tech Intellectual Properties, Inc.

Viiv Healthcare UK (no. 4) Limited

Sirard, Pierre

Levesque, Kathia

Thoraval, Dominique

John F Kadow

Tao Wang

Zhongxing Zhang

Nicholas A Meanwell

Kap-Sun Yeung

John A Bender

Zhiwei Yin

B Narasimhulu Naidu

Piyasena Hewawasam

Kyle E Parcella

Ying Han

Katharine A Grant-Young

Manoj Patel

Alicia Regueiro-Ren

Mark D Wittman

Yasutsugu Ueda

Kevin M Peese

Makonen Belema

Qiufen May Xue

Brett R Beno

Andrew Nickel

Robert G Gentles

Kyle J Eastman

Yong Tu

Edward H Ruediger

Min Ding

Timothy P Connolly

Zhong Yang

Lawrence G Hamann

Dolatrai M Vyas

Mark George Saulnier

Omar D Lopez

Thomas W Hudyma

Xiaofan Zheng

Harold A Mastalerz

Zhongyu Wang

David R Langley

Daniel H Deon

Clint A James

Michael A Walker

David J Carini

Nachimuthu Soundararajan

Shawn K Pack

Chung-Pin H Chen

David Kenneth Leahy

Dominique Thoraval

Pierre Sirard

Jacob Swidorski

Alan Xiangdong Wang

Zhizhen Barbara Zheng

Barry L Johnson

Jeffrey Lee Romine

Denis R St Laurent

Carol Bachand

Gan Wang

Prasanna Sivaprakasam

Louis Stanley Chupak

John D Matiskella

Ningning Xu

Rajesh Onkardas Bora

Peter D Senter

John K Thottathil

Ashvinikumar V Gavai

Murray A Kaplan

Lawrence B Snyder

Brian E Fink

Van N Nguyen

Gregory D Vite

Owen Brendan Wallace

John J Wright

Scott W Martin

Stanley V D'Andrea

Rico Lavoie

Zheng Liu

Ramkumar Rajamani

Henry S Wong

Shu-Hui Chen

Carl P Bergstrom

Vittorio Farina

Wen-Sen Li

Robert K Perrone

Kumaravel Selvakumar

Jerzy Golik

Paul Michael Scola

Takushi Kaneko

Andrew Charles Good

Eric P Gillis

David Bertil Frennesson

Margaret E Sorenson

Bradley C Pearce

Martin D Eastgate

Joydeep Kant

Michael S Bowsher

David G Kingston

Thomas Stephen Coulter

Xiaopeng Sang

Bin Zheng

Ke Chen

Pulicharla Nagalakshmi

Xian Liang

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: 

4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication

This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein:  Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein:

Salts of prodrugs of piperazine and substituted piperidine antiviral agents

The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. 

Benzofuran derivatives for the treatment of hepatitis C

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth. 

Inhibitors of human immunodeficiency virus replication

Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS. 

5-(n-[6,5]-fused bicyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV: 

Substituted benzofuran compounds for the treatment of hepatitis C

Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV. 

5-(N-fused tricyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV: 

Substituted 2-phenyl (AZA)benzofuran compounds for the treatment of hepatitis C

Compounds of formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. 

Macrocyclic benzofuran compounds for the treatment of hepatitis C

Disclosed are compounds of Formula (I), including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS. In the compounds of formula (I), Ris selected from hydrogen, alkyl, or cycloalkyl; Ris selected from tetrahydroisoquinolinyl and is substituted with 1 Rsubstituent and also with 0-3 halo or alkyl substituents; Ris selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, homopiperidinyl, homopiperazinyl, or homomorpholinyl, and is substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, and haloalkoxy; Ris selected from alkyl or haloalkyl; Ris alkyl; Ris selected from Ar, (Ar)alkyl, (chromanyl)alkyl, cyanocycloalkyl or (dihydrobenzodioxinyl)alkyl; and Aris phenyl substituted with 0-5 substituents selected from cyano, halo, alkyl, cycloalkyl, haloalkyl, hydroxy, alkoxy, haloalkoxy, (hydroxy)alkoxy, (alkoxy)alkoxy, phenoxy, benzyloxy, carboxy, phenyl, and cyanocycloalkyl. 

Substituted pyridines as inhibitors of human immunodeficiency virus replication

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. 

Compounds for the treatment of hepatitis C

Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication

Growing community of inventors

Wallingford, CT, United States of America

John F Kadow